---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-06-13T06:28:54.605799'
end_time: '2026-06-13T06:40:07.714783'
duration_seconds: 673.11
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: FBXO25
  gene_symbol: FBXO25
  uniprot_accession: Q8TCJ0
  protein_description: 'RecName: Full=F-box only protein 25;'
  gene_info: Name=FBXO25; Synonyms=FBX25;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: F-box-like_dom_sf. (IPR036047); FBX25/32. (IPR040394); FBXO25_C
    (PF27582); FBXO32_helical (PF27576)
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 28
artifact_count: 1
artifact_sources:
  edison_answer_artifacts: 1
artifacts:
- filename: artifact-00.md
  path: FBXO25-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8TCJ0
- **Protein Description:** RecName: Full=F-box only protein 25;
- **Gene Information:** Name=FBXO25; Synonyms=FBX25;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** F-box-like_dom_sf. (IPR036047); FBX25/32. (IPR040394); FBXO25_C (PF27582); FBXO32_helical (PF27576)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "FBXO25" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'FBXO25' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **FBXO25** (gene ID: FBXO25, UniProt: Q8TCJ0) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8TCJ0
- **Protein Description:** RecName: Full=F-box only protein 25;
- **Gene Information:** Name=FBXO25; Synonyms=FBX25;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** F-box-like_dom_sf. (IPR036047); FBX25/32. (IPR040394); FBXO25_C (PF27582); FBXO32_helical (PF27576)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "FBXO25" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'FBXO25' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **FBXO25** (gene ID: FBXO25, UniProt: Q8TCJ0) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Comprehensive Research Report: Human **FBXO25** (UniProt **Q8TCJ0**) Functional Annotation

### 0) Identity verification (mandatory)
The research below is restricted to **human FBXO25** encoding **F-box only protein 25** (UniProt **Q8TCJ0**). Primary literature explicitly studies FBXO25 as an F-box substrate-recognition subunit of an SCF/CRL1 ubiquitin ligase, including purification of SCF1(FBXO25) complexes containing **SKP1, CUL1, and ROC1/RBX1** in human cells, consistent with UniProt identity and expected F-box protein biology. (teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 3-4)

### 1) Key concepts and definitions (current understanding)

#### 1.1 F-box proteins and SCF/CRL1 E3 ubiquitin ligases
F-box proteins are substrate receptors within **SCF (SKP1–CUL1–F-box)** complexes (a subset of Cullin-RING ligases, CRL1). In this architecture, the **F-box motif** mediates binding to SKP1, while other regions of the F-box protein confer **substrate recognition**, bringing specific targets to the CUL1–RBX1 catalytic core for ubiquitin transfer and often proteasome-dependent degradation. For FBXO25 specifically, Teixeira et al. purified an active **SCF1(FBXO25)** complex from HEK293T cells that included **HA-SKP1, CUL1-FLAG, and Myc-Roc1 (RBX1)** together with tagged FBXO25, providing direct biochemical evidence of SCF membership. (teixeira2013thefboxprotein pages 3-4)

#### 1.2 What FBXO25 “does” at the molecular level
**Primary molecular function (best supported):** FBXO25 acts as the **substrate-recognition subunit** of an SCF1 E3 ligase that **ubiquitinates specific proteins**, thereby controlling their abundance and downstream transcriptional programs.

**Validated substrate:** The transcription factor **ELK-1** is the clearest experimentally validated endogenous substrate. FBXO25 physically associates with ELK-1 and promotes ELK-1 ubiquitination and proteasome-dependent degradation in human cells. (teixeira2013thefboxprotein pages 5-6, teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 7-8)

### 2) Subcellular localization and cellular context

#### 2.1 Nuclear localization and FBXO25-associated nuclear domains (FANDs)
FBXO25 is not merely diffuse in the nucleus; it localizes to discrete nuclear puncta termed **FBXO25-associated nuclear domains (FANDs)**. These FANDs are reported to co-localize with the **proteasome** and **ubiquitinated proteins**, suggesting FBXO25 participates in a nuclear proteostasis/ubiquitin signaling compartment. FAND integrity is sensitive to perturbations of actin polymerization and inhibition of RNA polymerase I, indicating regulated assembly and/or dependence on nuclear structural or transcriptional states. (teixeira2010identificationoffbxo25‐interacting pages 1-2, teixeira2010identificationoffbxo25‐interacting pages 4-6)

### 3) Mechanistic evidence for substrates, interactors, and pathways

#### 3.1 ELK-1 degradation and downstream MAPK/mitogen-responsive transcription
**Discovery/validation strategy:** Teixeira et al. used an **in-chip ubiquitination screen** on a human protein microarray to identify candidate substrates and then validated ELK-1. (teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 3-4)

**Key experimental evidence for ELK-1 as an SCF1(FBXO25) substrate:**
- **SCF complex formation:** FBXO25 forms SCF1 with SKP1/CUL1/Roc1 (RBX1). (teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 3-4)
- **Physical interaction:** Co-purification/co-IP shows FBXO25 associates with ELK-1; notably, an FBXO25 **ΔF-box mutant** still binds ELK-1, separating binding from ubiquitination function. (teixeira2013thefboxprotein pages 5-6)
- **Ubiquitination:** ELK-1 is ubiquitinated by SCF1(FBXO25) in vitro and in cells, with controls demonstrating dependency on intact ubiquitination machinery and the F-box for functional ubiquitination. (teixeira2013thefboxprotein pages 7-8, teixeira2013thefboxprotein pages 3-4)
- **Proteasome dependence:** ELK-1 turnover is accelerated by FBXO25 and is **blocked by epoxomicin**, showing proteasome-dependent degradation. (teixeira2013thefboxprotein pages 9-10, teixeira2013thefboxprotein pages 7-8)
- **Functional transcriptional consequence:** FBXO25 overexpression suppresses induction of ELK-1 target genes **c-fos** and **egr-1** following mitogen stimulation (PMA), consistent with reduced ELK-1 activity due to decreased ELK-1 protein levels. (teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 7-8)

**Interpretation:** This places FBXO25 as a regulator of mitogen-responsive transcriptional output through controlling ELK-1 stability in the nucleus. (teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 7-8)

#### 3.2 FBXO25 interaction network (proteomics) and nuclear organization
Teixeira et al. combined tandem affinity purification and mass spectrometry with yeast two-hybrid screening to identify an extensive FBXO25 interaction network, reporting **132 novel potential FBXO25-interacting partners**. (teixeira2010identificationoffbxo25‐interacting pages 1-2)

A prominent validated interactor is **β-actin**, reported to bind the N-terminus of FBXO25 and to be enriched in FBXO25 nuclear compartments (FANDs). In the yeast two-hybrid screen, β-actin had **63 hits**, suggesting a strong or recurrent interaction signal. (teixeira2010identificationoffbxo25‐interacting pages 1-2, teixeira2010identificationoffbxo25‐interacting pages 21-23)

**Interpretation:** These results support a model in which FBXO25 participates in a specialized nuclear compartment whose organization may be linked to nuclear actin and proteasome/ubiquitin-associated processes. (teixeira2010identificationoffbxo25‐interacting pages 1-2)

#### 3.3 Chromatin-linked pathway in osteogenic differentiation (ODIR1–FBXO25 axis)
A distinct functional axis implicates FBXO25 in chromatin modification during osteogenesis. In human umbilical cord-derived MSCs (hUC-MSCs), He et al. report that FBXO25 promotes **H2B K120 monoubiquitination (H2BK120ub)**, which is associated with increased **H3K4 trimethylation (H3K4me3)** and transcriptional activation of the osteogenic transcription factor **OSX (osterix/SP7)**. FBXO25 knockdown decreases H2BK120ub and H3K4me3, consistent with FBXO25 positively regulating this chromatin state. (he2019lncrnaodir1inhibits pages 8-11, he2019lncrnaodir1inhibits pages 15-16)

The lncRNA **ODIR1** is reported to bind FBXO25 and facilitate **proteasome-dependent degradation of FBXO25** by recruiting **CUL3**, thereby suppressing the FBXO25→H2BK120ub→H3K4me3→OSX pathway and inhibiting osteogenic differentiation. (he2019lncrnaodir1inhibits pages 8-11)

**Interpretation:** While FBXO25 is classically framed as a substrate adaptor promoting protein degradation, this study supports a role for FBXO25 in controlling a **histone ubiquitination mark** and downstream transcriptional programs in a differentiation context. (he2019lncrnaodir1inhibits pages 8-11)

### 4) Recent developments (prioritizing 2023–2024)

#### 4.1 2023: Functional genomic identification of Fbxo25 as a hypertrophy modulator
A 2023 study screened Cullin-RING ubiquitin ligases in neonatal rat cardiomyocytes using siRNA and automated microscopy, identifying **Fbxo25** depletion as a strong driver of increased basal cardiomyocyte size. Quantitatively, Fbxo25 knockdown increased cardiomyocyte area by **~37%** and increased **3H-isoleucine incorporation by ~41%**, and it upregulated hypertrophy markers **Anp** and **Bnp**. (fischer2023identificationofhypertrophymodulating pages 1-2)

In vivo, after transverse aortic constriction (TAC), Fbxo25 protein concentrations increased by **~4.5-fold** compared to control animals. (fischer2023identificationofhypertrophymodulating pages 1-2)

**Interpretation:** Although performed in rodent systems, these results elevate FBXO25/Fbxo25 as a candidate regulator of cardiac hypertrophy pathways and motivate identification of the relevant cardiac substrates and upstream regulators. (fischer2023identificationofhypertrophymodulating pages 1-2)

#### 4.2 2023: Clinical genomics observation—FBXO25–SEPT14 fusion in CML
A 2023 case report described a previously unreported **FBXO25–SEPT14 fusion** in a patient with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). The fusion joined **FBXO25 exon 4** to **SEPT14 exon 10**, detected via RNA-based NGS. The patient exhibited persistent suboptimal molecular response (BCR::ABL P210/ABL remained above clinically desirable thresholds across time) and acquired additional cytogenetic abnormalities; the authors suggest the fusion may be associated with TKI resistance, but emphasize the need for functional validation and additional cases. (liao2023ararefbxo25–sept14 pages 1-2, liao2023ararefbxo25–sept14 pages 2-5)

**Interpretation:** This is an early clinical signal (single-patient) that FBXO25 rearrangements may occur in hematologic malignancy contexts; causality for resistance is unproven. (liao2023ararefbxo25–sept14 pages 1-2)

#### 4.3 2024: Limited FBXO25-specific mechanistic expansion in accessible sources
A 2024 review on epigenetic regulation in bone metabolism was retrieved, but FBXO25-specific mechanistic content was not captured in the scanned segments available here. Consequently, the strongest FBXO25 mechanistic evidence in this corpus remains anchored in 2010/2013 (nuclear localization and ELK-1 substrate) plus 2019 (ODIR1 axis) and 2023 (cardiac phenotype screen). (teixeira2010identificationoffbxo25‐interacting pages 1-2, teixeira2013thefboxprotein pages 1-2, he2019lncrnaodir1inhibits pages 8-11, fischer2023identificationofhypertrophymodulating pages 1-2)

### 5) Current applications and real-world implementations

#### 5.1 Functional annotation pipelines in practice
FBXO25 is a good example of how E3 substrate identification is being operationalized using:
- **Protein microarray “in-chip ubiquitination”** screens to nominate candidate substrates, followed by biochemical validation (e.g., ELK-1). This is a scalable substrate-discovery approach for poorly annotated SCF adaptors. (teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 3-4)
- **Integrated proteomics** (tandem affinity purification + mass spectrometry + yeast two-hybrid) to build an interaction map and discover localization-associated partners (e.g., β-actin; SCF machinery). (teixeira2010identificationoffbxo25‐interacting pages 1-2, teixeira2010identificationoffbxo25‐interacting pages 4-6)

#### 5.2 Translational genetics and model-based functional validation (ADHD example)
Harich et al. illustrate an integrative workflow: family CNV discovery → large GWAS gene-based analysis → Drosophila overexpression modeling. They report FBXO25 gene-based association with ADHD in a GWAS meta-analysis with **n = 55,374**, including FBXO25 p = **0.010756**, and demonstrate that pan-neuronal overexpression of the fly orthologue increases nocturnal locomotor activity and reduces sleep. Behavioral assay sample sizes include **n = 64** and **n = 56** for overexpression lines versus **n = 63** controls, with significant p-values (e.g., night activity p = 0.0013 and p < 0.0001; sleep p = 0.0076 and p < 0.0001). (harich2020frommanto pages 6-8, harich2020frommanto pages 4-6)

#### 5.3 Clinical genomics reporting (CML fusion example)
The FBXO25–SEPT14 fusion report reflects real-world implementation of **RNA-based next-generation sequencing** and fusion calling in oncology. The proposed resistance association is hypothesis-generating rather than actionable at present. (liao2023ararefbxo25–sept14 pages 1-2, liao2023ararefbxo25–sept14 pages 2-5)

### 6) Expert opinions and analysis (authoritative synthesis within retrieved sources)

- **FBXO25’s “primary function”** is best supported as an **SCF1/CRL1 substrate adaptor** controlling protein ubiquitination and proteasome-dependent degradation, with ELK-1 as a validated substrate linking FBXO25 to mitogen-responsive transcriptional programs. (teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 7-8)
- The localization to **FANDs**, enriched for proteasome and ubiquitinated proteins, suggests FBXO25 contributes to a **nuclear ubiquitin–proteasome microenvironment**, potentially enabling efficient turnover of nuclear regulatory factors. (teixeira2010identificationoffbxo25‐interacting pages 1-2)
- The ODIR1–FBXO25 axis suggests **context-dependent biology**: FBXO25 may modulate differentiation programs through chromatin-associated ubiquitination (H2BK120ub) in addition to classical substrate degradation. This broadens the plausible functional landscape for FBXO25 beyond single-substrate turnover. (he2019lncrnaodir1inhibits pages 8-11)
- Recent cardiomyocyte screening evidence motivates the hypothesis that FBXO25-containing CRLs may buffer hypertrophic growth; the mechanistic substrate(s) in cardiomyocytes remain to be established. (fischer2023identificationofhypertrophymodulating pages 1-2)

### 7) Statistics and key quantitative data (from recent and foundational studies)
Key quantitative observations relevant for functional annotation include:
- **132** novel potential FBXO25 interactors identified by integrated proteomics; β-actin had **63** hits in yeast two-hybrid. (teixeira2010identificationoffbxo25‐interacting pages 1-2, teixeira2010identificationoffbxo25‐interacting pages 21-23)
- **75** putative SCF1(FBXO25) substrates identified by protoarray ubiquitination (candidates; not all validated). (teixeira2013thefboxprotein pages 3-4)
- Cardiomyocyte hypertrophy phenotypes: Fbxo25 knockdown increased cell size by **~37%**, increased protein synthesis proxy by **~41%**, and TAC increased Fbxo25 protein by **~4.5-fold**. (fischer2023identificationofhypertrophymodulating pages 1-2)
- ADHD genetics/modeling: GWAS meta-analysis **n = 55,374**, FBXO25 gene-based p = **0.010756**; fly behavioral assays with n ≈ **56–64** per overexpression line and significant p-values for hyperactivity/sleep phenotypes. (harich2020frommanto pages 6-8, harich2020frommanto pages 4-6)
- CML fusion: single patient; fusion joins **FBXO25 exon 4** to **SEPT14 exon 10** (hypothesis-generating). (liao2023ararefbxo25–sept14 pages 1-2, liao2023ararefbxo25–sept14 pages 2-5)

### 8) Consolidated summary table
The following table consolidates the most supported claims, evidence types, dates, and URLs.

| Category | Key finding | Evidence type | Key citation (author-year) | Publication date | URL/DOI |
|---|---|---|---|---|---|
| Identity/domains | Human FBXO25 corresponds to UniProt Q8TCJ0, “F-box only protein 25,” an F-box substrate-recognition protein in an SCF/CRL1 E3 ligase. Primary literature consistently treats it as a human nuclear F-box protein rather than a different FBXO family member (teixeira2013thefboxprotein pages 1-2, teixeira2010identificationoffbxo25‐interacting pages 1-2). | Primary study, database summary | Teixeira 2013; Teixeira 2010 | 2013-09; 2010-08 | https://doi.org/10.1074/jbc.M113.504308; https://doi.org/10.1002/pmic.200900419 |
| SCF complex | FBXO25 assembles an active SCF1(FBXO25) complex with SKP1, CUL1, and Roc1/RBX1 in HEK293T cells, supporting its core molecular role as the substrate adaptor for ubiquitination. Complex purification used tagged HA-SKP1, CUL1-FLAG, Myc-Roc1, and GST-HA-FBXO25-FLAG (teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 3-4). | Primary study | Teixeira 2013 | 2013-09 | https://doi.org/10.1074/jbc.M113.504308 |
| Localization | FBXO25 localizes to distinct nuclear puncta termed FBXO25-associated nuclear domains (FANDs), which co-localize with proteasomes and ubiquitinated proteins. FAND integrity is disrupted by actin depolymerization and by RNA polymerase I inhibition, supporting a regulated nuclear-compartment function (teixeira2010identificationoffbxo25‐interacting pages 1-2, teixeira2010identificationoffbxo25‐interacting pages 4-6). | Primary study | Teixeira 2010 | 2010-08 | https://doi.org/10.1002/pmic.200900419 |
| Validated substrates | ELK-1 is the best-supported endogenous FBXO25 substrate. FBXO25 binds ELK-1, promotes its ubiquitination, accelerates ELK-1 turnover in methionine-chase assays, and the degradation is blocked by epoxomicin, demonstrating proteasome dependence; FBXO25 overexpression also suppresses ELK-1 target genes c-fos and egr-1 (teixeira2013thefboxprotein pages 9-10, teixeira2013thefboxprotein pages 5-6, teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 7-8). | Primary study | Teixeira 2013 | 2013-09 | https://doi.org/10.1074/jbc.M113.504308 |
| Other reported targets/candidates | A protoarray ubiquitination screen identified 75 putative SCF1(FBXO25) substrates from ~8,000 human proteins; named candidates include GTF2B, ODF2, SAMHD1, RPS10, ADRBK1, CDK9, EGFR, and RABEP2. These are candidates rather than comparably validated substrates, so confidence is lower than for ELK-1 (teixeira2013thefboxprotein pages 7-8, teixeira2013thefboxprotein pages 9-10, teixeira2013thefboxprotein pages 3-4). | Primary study | Teixeira 2013 | 2013-09 | https://doi.org/10.1074/jbc.M113.504308 |
| Regulatory interactions | An integrated proteomics approach identified 132 novel potential FBXO25-interacting partners; β-actin was a validated interactor that binds the N-terminus of FBXO25 and is enriched in FANDs. Proteomics also recovered major SCF-related components, consistent with FBXO25 acting in a broader nuclear interaction network (teixeira2010identificationoffbxo25‐interacting pages 1-2, teixeira2010identificationoffbxo25‐interacting pages 4-6, teixeira2010identificationoffbxo25‐interacting pages 21-23). | Primary study | Teixeira 2010 | 2010-08 | https://doi.org/10.1002/pmic.200900419 |
| Regulatory interactions | In hUC-MSCs, lncRNA ODIR1 binds FBXO25 and promotes its proteasome-dependent degradation by recruiting CUL3; FBXO25 in turn promotes H2BK120 monoubiquitination and downstream H3K4me3, increasing transcription of the osteogenic factor OSX. This places FBXO25 in a chromatin-linked regulatory axis rather than only a classic protein-degradation role (he2019lncrnaodir1inhibits pages 8-11, he2019lncrnaodir1inhibits pages 15-16). | Primary study | He 2019 | 2019-12 | https://doi.org/10.1038/s41419-019-2148-2 |
| Phenotypes/disease links | In neonatal rat cardiomyocytes, Fbxo25 depletion increased cell size by ~37% and 3H-isoleucine incorporation by ~41%, and upregulated Anp/Bnp; in vivo, Fbxo25 protein increased ~4.5-fold after transverse aortic constriction. These data support a conserved antihypertrophic role, but they are from rodent models rather than direct human functional experiments (fischer2023identificationofhypertrophymodulating pages 1-2). | Primary study, model-organism | Fischer 2023 | 2023-03 | https://doi.org/10.3389/fphys.2023.1134339 |
| Phenotypes/disease links | Human genetic and fly-model evidence links FBXO25 to ADHD-related phenotypes. In a large ADHD GWAS meta-analysis (n=55,374), gene-based analysis implicated FBXO25 (reported p=0.010756), and Drosophila pan-neuronal overexpression increased nocturnal locomotor activity and reduced sleep; sample sizes were n=64 and n=56 for two overexpression lines versus n=63 controls, with p-values 0.0013 to <0.0001 depending on assay (harich2020frommanto pages 6-8, harich2020frommanto pages 3-4, OpenTargets Search: -FBXO25, harich2020frommanto pages 4-6, harich2020frommanto pages 1-2). | Primary study, database summary, model-organism | Harich 2020; OpenTargets | 2020-12; OpenTargets accessed in current query | https://doi.org/10.1111/jcpp.13161; https://platform.opentargets.org/target/ENSG00000147364 |
| Phenotypes/disease links | A single-patient case report described a novel FBXO25–SEPT14 fusion in chronic myeloid leukemia, joining FBXO25 exon 4 to SEPT14 exon 10, in a patient with persistent suboptimal molecular response to TKIs. The authors suggest a possible association with TKI resistance, but evidence is limited to one observational case without functional validation (liao2023ararefbxo25–sept14 pages 1-2, liao2023ararefbxo25–sept14 pages 5-6, liao2023ararefbxo25–sept14 pages 2-5). | Primary study, single-case report | Liao 2023 | 2023-09 | https://doi.org/10.1515/oncologie-2023-0217 |
| Key quantitative data | Quantitative highlights across studies: 132 potential interactors and β-actin with 63 yeast-two-hybrid hits; 75 putative ubiquitination substrates; cardiac phenotypes of ~37% larger cardiomyocyte area, ~41% higher protein synthesis, and ~4.5-fold TAC-induced protein increase; ADHD GWAS meta-analysis n=55,374 with FBXO25 p=0.010756; Drosophila overexpression ~450% or ~650% expression versus control with behavioral sample sizes n=64, n=56, n=63 and significant night-activity/sleep effects; one reported FBXO25–SEPT14 CML case (teixeira2010identificationoffbxo25‐interacting pages 21-23, fischer2023identificationofhypertrophymodulating pages 1-2, harich2020frommanto pages 6-8, OpenTargets Search: -FBXO25, harich2020frommanto pages 4-6, liao2023ararefbxo25–sept14 pages 2-5). | Primary study, database summary | Teixeira 2010; Fischer 2023; Harich 2020; OpenTargets; Liao 2023 | 2010-08; 2023-03; 2020-12; OpenTargets accessed in current query; 2023-09 | https://doi.org/10.1002/pmic.200900419; https://doi.org/10.3389/fphys.2023.1134339; https://doi.org/10.1111/jcpp.13161; https://platform.opentargets.org/target/ENSG00000147364; https://doi.org/10.1515/oncologie-2023-0217 |


*Table: This table summarizes the best-supported validated and proposed functions of human FBXO25, emphasizing molecular function, localization, substrates, regulatory interactions, and disease links. It also flags where evidence comes from model systems, candidate screens, or a single-case clinical report.*

### 9) Key gaps and near-term research directions (evidence-based)
1. **Substrate landscape beyond ELK-1**: 75 protoarray candidates provide hypotheses but require rigorous validation (endogenous interaction, ubiquitination mapping, degradation dependence, phenotypic linkage). (teixeira2013thefboxprotein pages 3-4)
2. **Mechanism of H2BK120ub regulation**: The FBXO25-dependent increase in H2BK120ub suggests either a direct histone-centered ubiquitination role or indirect regulation of the H2B ubiquitination machinery; molecular intermediates remain incompletely defined in the extracted evidence. (he2019lncrnaodir1inhibits pages 8-11)
3. **Cardiac biology translation to humans**: 2023 hypertrophy findings are in rat cells/rodent in vivo; establishing human relevance will require human cardiomyocyte models and identification of the relevant cardiac substrates/pathways. (fischer2023identificationofhypertrophymodulating pages 1-2)
4. **Clinical significance of FBXO25 fusions**: The FBXO25–SEPT14 fusion is currently a single-case observation; causal links to TKI resistance require functional assays and additional cohorts. (liao2023ararefbxo25–sept14 pages 1-2)

### 10) Source list (URLs and publication dates highlighted)
- Teixeira FR et al. **2010-08**. *Identification of FBXO25-interacting proteins using an integrated proteomics approach.* PROTEOMICS. https://doi.org/10.1002/pmic.200900419 (teixeira2010identificationoffbxo25‐interacting pages 1-2, teixeira2010identificationoffbxo25‐interacting pages 4-6, teixeira2010identificationoffbxo25‐interacting pages 21-23)
- Teixeira FR et al. **2013-09**. *The F-box protein FBXO25 promotes the proteasome-dependent degradation of ELK-1 protein.* J Biol Chem. https://doi.org/10.1074/jbc.M113.504308 (teixeira2013thefboxprotein pages 1-2, teixeira2013thefboxprotein pages 7-8, teixeira2013thefboxprotein pages 3-4)
- He S et al. **2019-12**. *LncRNA ODIR1 inhibits osteogenic differentiation of hUC-MSCs through the FBXO25/H2BK120ub/H3K4me3/OSX axis.* Cell Death & Disease. https://doi.org/10.1038/s41419-019-2148-2 (he2019lncrnaodir1inhibits pages 8-11, he2019lncrnaodir1inhibits pages 15-16)
- Fischer M et al. **2023-03**. *Identification of hypertrophy-modulating Cullin-RING ubiquitin ligases in primary cardiomyocytes.* Front Physiol. https://doi.org/10.3389/fphys.2023.1134339 (fischer2023identificationofhypertrophymodulating pages 1-2)
- Liao Y et al. **2023-09**. *A rare FBXO25–SEPT14 fusion in a patient with chronic myeloid leukemia…: a case report.* Oncologie. https://doi.org/10.1515/oncologie-2023-0217 (liao2023ararefbxo25–sept14 pages 1-2, liao2023ararefbxo25–sept14 pages 2-5)
- Harich B et al. **2020-12**. *From man to fly – convergent evidence links FBXO25 to ADHD…* J Child Psychol Psychiatry. https://doi.org/10.1111/jcpp.13161 (harich2020frommanto pages 6-8, harich2020frommanto pages 4-6)
- Open Targets Platform (accessed via tool query; target ENSG00000147364/FBXO25). https://platform.opentargets.org/target/ENSG00000147364 (OpenTargets Search: -FBXO25)


References

1. (teixeira2013thefboxprotein pages 1-2): Felipe R. Teixeira, Adriana O. Manfiolli, Cláudia S. Soares, Munira M.A. Baqui, Tie Koide, and Marcelo D. Gomes. The f-box protein fbxo25 promotes the proteasome-dependent degradation of elk-1 protein. Journal of Biological Chemistry, 288:28152-28162, Sep 2013. URL: https://doi.org/10.1074/jbc.m113.504308, doi:10.1074/jbc.m113.504308. This article has 24 citations and is from a domain leading peer-reviewed journal.

2. (teixeira2013thefboxprotein pages 3-4): Felipe R. Teixeira, Adriana O. Manfiolli, Cláudia S. Soares, Munira M.A. Baqui, Tie Koide, and Marcelo D. Gomes. The f-box protein fbxo25 promotes the proteasome-dependent degradation of elk-1 protein. Journal of Biological Chemistry, 288:28152-28162, Sep 2013. URL: https://doi.org/10.1074/jbc.m113.504308, doi:10.1074/jbc.m113.504308. This article has 24 citations and is from a domain leading peer-reviewed journal.

3. (teixeira2013thefboxprotein pages 5-6): Felipe R. Teixeira, Adriana O. Manfiolli, Cláudia S. Soares, Munira M.A. Baqui, Tie Koide, and Marcelo D. Gomes. The f-box protein fbxo25 promotes the proteasome-dependent degradation of elk-1 protein. Journal of Biological Chemistry, 288:28152-28162, Sep 2013. URL: https://doi.org/10.1074/jbc.m113.504308, doi:10.1074/jbc.m113.504308. This article has 24 citations and is from a domain leading peer-reviewed journal.

4. (teixeira2013thefboxprotein pages 7-8): Felipe R. Teixeira, Adriana O. Manfiolli, Cláudia S. Soares, Munira M.A. Baqui, Tie Koide, and Marcelo D. Gomes. The f-box protein fbxo25 promotes the proteasome-dependent degradation of elk-1 protein. Journal of Biological Chemistry, 288:28152-28162, Sep 2013. URL: https://doi.org/10.1074/jbc.m113.504308, doi:10.1074/jbc.m113.504308. This article has 24 citations and is from a domain leading peer-reviewed journal.

5. (teixeira2010identificationoffbxo25‐interacting pages 1-2): Felipe R. Teixeira, Sami Yokoo, Carlos A. Gartner, Adriana O. Manfiolli, Munira M. A. Baqui, Eliana M. Assmann, Ana Leticia G. C. Maragno, Huijun Yu, Primal de Lanerolle, Jörg Kobarg, Steven P. Gygi, and Marcelo Damário Gomes. Identification of fbxo25‐interacting proteins using an integrated proteomics approach. PROTEOMICS, 10:2746-2757, Aug 2010. URL: https://doi.org/10.1002/pmic.200900419, doi:10.1002/pmic.200900419. This article has 11 citations and is from a peer-reviewed journal.

6. (teixeira2010identificationoffbxo25‐interacting pages 4-6): Felipe R. Teixeira, Sami Yokoo, Carlos A. Gartner, Adriana O. Manfiolli, Munira M. A. Baqui, Eliana M. Assmann, Ana Leticia G. C. Maragno, Huijun Yu, Primal de Lanerolle, Jörg Kobarg, Steven P. Gygi, and Marcelo Damário Gomes. Identification of fbxo25‐interacting proteins using an integrated proteomics approach. PROTEOMICS, 10:2746-2757, Aug 2010. URL: https://doi.org/10.1002/pmic.200900419, doi:10.1002/pmic.200900419. This article has 11 citations and is from a peer-reviewed journal.

7. (teixeira2013thefboxprotein pages 9-10): Felipe R. Teixeira, Adriana O. Manfiolli, Cláudia S. Soares, Munira M.A. Baqui, Tie Koide, and Marcelo D. Gomes. The f-box protein fbxo25 promotes the proteasome-dependent degradation of elk-1 protein. Journal of Biological Chemistry, 288:28152-28162, Sep 2013. URL: https://doi.org/10.1074/jbc.m113.504308, doi:10.1074/jbc.m113.504308. This article has 24 citations and is from a domain leading peer-reviewed journal.

8. (teixeira2010identificationoffbxo25‐interacting pages 21-23): Felipe R. Teixeira, Sami Yokoo, Carlos A. Gartner, Adriana O. Manfiolli, Munira M. A. Baqui, Eliana M. Assmann, Ana Leticia G. C. Maragno, Huijun Yu, Primal de Lanerolle, Jörg Kobarg, Steven P. Gygi, and Marcelo Damário Gomes. Identification of fbxo25‐interacting proteins using an integrated proteomics approach. PROTEOMICS, 10:2746-2757, Aug 2010. URL: https://doi.org/10.1002/pmic.200900419, doi:10.1002/pmic.200900419. This article has 11 citations and is from a peer-reviewed journal.

9. (he2019lncrnaodir1inhibits pages 8-11): Shiwei He, Sheng Yang, Yanru Zhang, Xiaoling Li, Dan Gao, Yancheng Zhong, Lihua Cao, Haotian Ma, Ying Liu, Guiyuan Li, Shuping Peng, and Cijun Shuai. Lncrna odir1 inhibits osteogenic differentiation of huc-mscs through the fbxo25/h2bk120ub/h3k4me3/osx axis. Cell Death &amp; Disease, Dec 2019. URL: https://doi.org/10.1038/s41419-019-2148-2, doi:10.1038/s41419-019-2148-2. This article has 117 citations and is from a peer-reviewed journal.

10. (he2019lncrnaodir1inhibits pages 15-16): Shiwei He, Sheng Yang, Yanru Zhang, Xiaoling Li, Dan Gao, Yancheng Zhong, Lihua Cao, Haotian Ma, Ying Liu, Guiyuan Li, Shuping Peng, and Cijun Shuai. Lncrna odir1 inhibits osteogenic differentiation of huc-mscs through the fbxo25/h2bk120ub/h3k4me3/osx axis. Cell Death &amp; Disease, Dec 2019. URL: https://doi.org/10.1038/s41419-019-2148-2, doi:10.1038/s41419-019-2148-2. This article has 117 citations and is from a peer-reviewed journal.

11. (fischer2023identificationofhypertrophymodulating pages 1-2): Maximillian Fischer, Moritz Jakab, Marc N. Hirt, Tessa R. Werner, Stefan Engelhardt, and Antonio Sarikas. Identification of hypertrophy-modulating cullin-ring ubiquitin ligases in primary cardiomyocytes. Frontiers in Physiology, Mar 2023. URL: https://doi.org/10.3389/fphys.2023.1134339, doi:10.3389/fphys.2023.1134339. This article has 5 citations.

12. (liao2023ararefbxo25–sept14 pages 1-2): Yun Liao, Jiayue Liu, Mengyu Wei, Rongrong Chen, Xiaomin Chen, Haoshu Zhong, Yang Liu, Hao Xiong, and Chunlan Huang. A rare fbxo25–sept14 fusion in a patient with chronic myeloid leukemia treatment to tyrosine kinase inhibitors: a case report. Oncologie, 25:743-748, Sep 2023. URL: https://doi.org/10.1515/oncologie-2023-0217, doi:10.1515/oncologie-2023-0217. This article has 0 citations and is from a peer-reviewed journal.

13. (liao2023ararefbxo25–sept14 pages 2-5): Yun Liao, Jiayue Liu, Mengyu Wei, Rongrong Chen, Xiaomin Chen, Haoshu Zhong, Yang Liu, Hao Xiong, and Chunlan Huang. A rare fbxo25–sept14 fusion in a patient with chronic myeloid leukemia treatment to tyrosine kinase inhibitors: a case report. Oncologie, 25:743-748, Sep 2023. URL: https://doi.org/10.1515/oncologie-2023-0217, doi:10.1515/oncologie-2023-0217. This article has 0 citations and is from a peer-reviewed journal.

14. (harich2020frommanto pages 6-8): Benjamin Harich, Marieke Klein, Charlotte W. Ockeloen, Monique van der Voet, Marlies Schimmel‐Naber, Nicole de Leeuw, Annette Schenck, and Barbara Franke. From man to fly – convergent evidence links fbxo25 to adhd and comorbid psychiatric phenotypes. Journal of Child Psychology and Psychiatry, and Allied Disciplines, 61:545-555, Dec 2020. URL: https://doi.org/10.1111/jcpp.13161, doi:10.1111/jcpp.13161. This article has 15 citations.

15. (harich2020frommanto pages 4-6): Benjamin Harich, Marieke Klein, Charlotte W. Ockeloen, Monique van der Voet, Marlies Schimmel‐Naber, Nicole de Leeuw, Annette Schenck, and Barbara Franke. From man to fly – convergent evidence links fbxo25 to adhd and comorbid psychiatric phenotypes. Journal of Child Psychology and Psychiatry, and Allied Disciplines, 61:545-555, Dec 2020. URL: https://doi.org/10.1111/jcpp.13161, doi:10.1111/jcpp.13161. This article has 15 citations.

16. (harich2020frommanto pages 3-4): Benjamin Harich, Marieke Klein, Charlotte W. Ockeloen, Monique van der Voet, Marlies Schimmel‐Naber, Nicole de Leeuw, Annette Schenck, and Barbara Franke. From man to fly – convergent evidence links fbxo25 to adhd and comorbid psychiatric phenotypes. Journal of Child Psychology and Psychiatry, and Allied Disciplines, 61:545-555, Dec 2020. URL: https://doi.org/10.1111/jcpp.13161, doi:10.1111/jcpp.13161. This article has 15 citations.

17. (OpenTargets Search: -FBXO25): Open Targets Query (-FBXO25, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

18. (harich2020frommanto pages 1-2): Benjamin Harich, Marieke Klein, Charlotte W. Ockeloen, Monique van der Voet, Marlies Schimmel‐Naber, Nicole de Leeuw, Annette Schenck, and Barbara Franke. From man to fly – convergent evidence links fbxo25 to adhd and comorbid psychiatric phenotypes. Journal of Child Psychology and Psychiatry, and Allied Disciplines, 61:545-555, Dec 2020. URL: https://doi.org/10.1111/jcpp.13161, doi:10.1111/jcpp.13161. This article has 15 citations.

19. (liao2023ararefbxo25–sept14 pages 5-6): Yun Liao, Jiayue Liu, Mengyu Wei, Rongrong Chen, Xiaomin Chen, Haoshu Zhong, Yang Liu, Hao Xiong, and Chunlan Huang. A rare fbxo25–sept14 fusion in a patient with chronic myeloid leukemia treatment to tyrosine kinase inhibitors: a case report. Oncologie, 25:743-748, Sep 2023. URL: https://doi.org/10.1515/oncologie-2023-0217, doi:10.1515/oncologie-2023-0217. This article has 0 citations and is from a peer-reviewed journal.

## Artifacts

- [Edison artifact artifact-00](FBXO25-deep-research-falcon_artifacts/artifact-00.md)

## Citations

1. teixeira2013thefboxprotein pages 3-4
2. teixeira2013thefboxprotein pages 5-6
3. fischer2023identificationofhypertrophymodulating pages 1-2
4. teixeira2013thefboxprotein pages 1-2
5. teixeira2013thefboxprotein pages 7-8
6. teixeira2013thefboxprotein pages 9-10
7. harich2020frommanto pages 6-8
8. harich2020frommanto pages 4-6
9. harich2020frommanto pages 3-4
10. harich2020frommanto pages 1-2
11. https://doi.org/10.1074/jbc.M113.504308;
12. https://doi.org/10.1002/pmic.200900419
13. https://doi.org/10.1074/jbc.M113.504308
14. https://doi.org/10.1038/s41419-019-2148-2
15. https://doi.org/10.3389/fphys.2023.1134339
16. https://doi.org/10.1111/jcpp.13161;
17. https://platform.opentargets.org/target/ENSG00000147364
18. https://doi.org/10.1515/oncologie-2023-0217
19. https://doi.org/10.1002/pmic.200900419;
20. https://doi.org/10.3389/fphys.2023.1134339;
21. https://platform.opentargets.org/target/ENSG00000147364;
22. https://doi.org/10.1111/jcpp.13161
23. https://doi.org/10.1074/jbc.m113.504308,
24. https://doi.org/10.1002/pmic.200900419,
25. https://doi.org/10.1038/s41419-019-2148-2,
26. https://doi.org/10.3389/fphys.2023.1134339,
27. https://doi.org/10.1515/oncologie-2023-0217,
28. https://doi.org/10.1111/jcpp.13161,